1-8 of 8
Jostein Dahle, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Tara Helen Dowling Dowling Steinsland, MSc, Stein-Erik Gullaksen, MS, PhD, Geir Bredholt, PhD, Calum Leitch, PhD, Mireia Mayoral Safont, BS, Øystein Bruserud, MD PhD, Mihaela Popa, Astri Maaland, Helen Heyerdahl, PhD, Jostein Dahle, PhD, Bjorn T. Gjertsen, MD PhD, Emmet Mccormack, BSc, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26.
https://doi.org/10.1182/blood-2020-142899
Published: 2020
Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2574.
https://doi.org/10.1182/blood-2019-123287
Published: 2019
Journal Articles

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Amal Saidi, PhD, Astri Maaland, Julien Torgue, PhD, Helen Heyerdahl, PhD, Jostein Dahle, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4422.
https://doi.org/10.1182/blood-2018-99-110297
Published: 2018
Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1371.
https://doi.org/10.1182/blood-2018-99-110200
Published: 2018
Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2015) 126 (23): 5118.
https://doi.org/10.1182/blood.V126.23.5118.5118
Published: 2015
Journal Articles

Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo

Ada H.V. Repetto-Llamazares, PhD, Roy Hartvig Larsen, PhD, Landsverk Kirsti, PhD, Trond Stokke, PhD, Bergthora Eiriksdottir, PhD, Roman Generalov, MSc, Jostein Dahle, PhD
Journal: Blood
Blood (2015) 126 (23): 3245.
https://doi.org/10.1182/blood.V126.23.3245.3245
Published: 2015
Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3094.
https://doi.org/10.1182/blood.V124.21.3094.3094
Published: 2014
Journal Articles

Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,

Jostein Dahle, PhD, Ada Repetto, Camilla Sivertsen Mollatt, Katrine Brustad Melhus, Øyvind Sverre Bruland, MD, PhD, Arne Kolstad, MD, PhD, Roy Hartvig Larsen, PhD
Journal: Blood
Blood (2011) 118 (21): 3732.
https://doi.org/10.1182/blood.V118.21.3732.3732
Published: 2011